What Is Semaglutide? A Simple Overview
Wondering what semaglutide is and how it works? Here’s a simple overview and how to connect with a licensed provider through Eden.
Starting semaglutide? Learn what to expect from your weekly injection, how it works, and what to ask your licensed provider.
If you're considering starting semaglutide, you might be wondering what to expect from the injection process. Whether you’ve been prescribed a GLP-1 medication for metabolic health or weight-related concerns, understanding how the injection works can help you feel more confident as you begin.
This guide will walk you through what semaglutide is, how it's administered, what you might feel after your first few doses, and when to reach out to a licensed healthcare provider with questions.
Semaglutide is a GLP-1 receptor agonist, a medication that mimics a natural hormone involved in appetite, digestion, and insulin response. It’s available in several FDA-approved products, including:
Semaglutide is typically delivered via a once-weekly subcutaneous injection, which means it's administered just under the skin. It's not given intravenously or taken as a daily pill (except in the case of Rybelsus®, a separate oral version of semaglutide).
{{primary-cta}}
Semaglutide injections are given once a week, on the same day each week, unless your provider instructs otherwise.
Most individuals are taught how to self-administer the injection at home. The process is designed to be quick and straightforward, using a pen-style injector with a very fine needle.
If you're using a prefilled pen, your licensed healthcare provider or pharmacist will provide you with detailed instructions on how to prepare and administer the medication safely.
Many people report that the semaglutide injection feels similar to other routine subcutaneous injections, typically a brief pinch or slight pressure. The needle is small and thin, and the injection usually takes less than 10 seconds.
You may feel a small amount of soreness or redness at the injection site afterward. If that occurs, rotating the injection site each week (thigh one week, abdomen the next) may help minimize irritation.
If you experience persistent discomfort, consult your licensed healthcare provider for guidance.
Your provider may start you on a low dose (such as 0.25 mg), which may allow your body to adjust to the medication. This period may help minimize side effects, like nausea or bloating.
If tolerated, your provider may gradually increase your dose every 4 weeks until reaching a maintenance dose (which varies by medication and individual need).
Some people may begin to notice:
These effects are common early in treatment and may improve with time.
{{primary-cta}}
Semaglutide is designed to work gradually. While some individuals notice changes in appetite or food preferences within the first few weeks, visible weight-related results may take 8 to 12 weeks or more, especially when paired with lifestyle changes.
In the STEP 1 clinical trial, participants taking semaglutide 2.4 mg experienced an average weight reduction of 14.9% over 68 weeks. The GLP-1 formulation used in this trial is the same as the one that was later approved and marketed under the brand name Wegovy®, specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related condition.
Each person’s experience is different, and your provider can help set realistic expectations based on your health profile.
You should speak with your licensed provider if you experience:
Having regular check-ins can help ensure your treatment is progressing safely and effectively.
{{primary-cta}}
Eden is neither a pharmacy nor a healthcare provider. Instead, Eden is a digital health platform that connects individuals with independent, licensed healthcare providers who evaluate whether medications like semaglutide are appropriate based on your medical history and goals.
If a provider prescribes treatment, medications are filled by state-licensed pharmacies and shipped directly to your door for convenience and privacy.
Eden does not produce or compound any medications. Our role is to help simplify access to trusted care.
Starting semaglutide injections may feel like a big step, but understanding how they work can help make the experience more comfortable and empowering.
From how the injection feels to what to expect in the first few weeks, the key is staying informed and connected with a licensed healthcare provider. Eden is here to help you start that journey, on your terms.
Curious if semaglutide is right for you? Begin your consultation with a licensed provider and receive personalized answers tailored to your health goals.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Drugs@FDA: FDA-Approved drugs. (n.d.). FDA. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183